StockNews.AI
MRNA
Investopedia
218 days

S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast

1. Moderna lowered 2025 revenue guidance by $1 billion, impacting investor confidence. 2. Shares plummeted 16.8% after announcing cost cuts totaling $1.5 billion. 3. Revenue is expected to rely on COVID-19 and RSV vaccines in second half.

5m saved
Insight
Article

FAQ

Why Bearish?

Lowered revenue guidance and sharp stock decline indicate negative investor sentiment, common in biotech.

How important is it?

The substantial guidance cut directly affects investor expectations and stock performance.

Why Short Term?

Immediate market reactions suggest MRNA will experience volatility until earnings stabilizes.

Related Companies

Related News